ArticleCancer immunology, immunotherapy : CII2026

Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts.

Ryo Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.